- Advertise
- About OncLive
- Editorial Board
- CureToday.com
- TargetedOnc.com
- CancerNetwork.com
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
VCU Massey Cancer Center | Strategic Alliance Partners
A National Cancer Institute-designated cancer center in Richmond, Va., VCU Massey Cancer Center conducts basic, translational, clinical and population sciences cancer research, provides state-of-the-art treatments and clinical trials, and promotes cancer prevention and education. Since 1974, Massey has served as an internationally recognized center of excellence. Its 1,000-plus researchers, clinicians and staff members are dedicated to improving the quality of human life by developing and delivering effective means to prevent, control and ultimately cure cancer.
Latest from VCU Massey Cancer Center
Dr. Randall on Unmet Needs in Platinum-Resistant Ovarian Cancer
November 17, 2020
Video
Leslie M. Randall, MD, MAS, discusses the unmet needs in platinum-resistant ovarian cancer.
Dr. Geyer on Challenges in HER2+ Metastatic Breast Cancer Management
September 19, 2019
Video
Charles E. Geyer, Jr, MD, professor of medicine, Virginia Commonwealth University School of Medicine; associate director for clinical research and Harrigan, Haw, Luck Families chair in Cancer Research, Massey Cancer Center, discusses ongoing challenges in the management of patients with metastatic HER2-positive breast cancer.
Expert Expects T-DM1 to Transform Treatment in HER2+ Breast Cancer
January 29, 2019
Article
Charles E. Geyer, Jrm, MD, discusses the clinical implications of the KATHERINE trial and the outlook for T-DM1 in patients with HER2-positive breast cancer.
Dr. Geyer on Impact of Targeted Agents in HER2+ Breast Cancer
January 22, 2019
Video
Charles E. Geyer, Jr, MD, professor of medicine, Virginia Commonwealth University School of Medicine; associate director for clinical research and Harrigan, Haw, Luck Families chair in Cancer Research, Massey Cancer Center, discusses the impact of targeted agents in HER2-positive breast cancer.
Dr. Geyer Discusses Pertuzumab in HER2+ Breast Cancer
December 29, 2018
Video
Charles E. Geyer, Jr, MD, professor of medicine, Virginia Commonwealth University School of Medicine; associate director for clinical research and Harrigan, Haw, Luck Families chair in Cancer Research, Massey Cancer Center, discusses pertuzumab in HER2-positive breast cancer.
Dr. Geyer on the Rationale for the KATHERINE Trial in HER2-Positive Breast Cancer
December 11, 2018
Video
Charles E. Geyer, Jr, MD, professor of medicine, Virginia Commonwealth University School of Medicine; associate director for clinical research and Harrigan, Haw, Luck Families chair in Cancer Research, Massey Cancer Center, discusses the rationale and results of the phase III KATHERINE trial in HER2-positive breast cancer.